Acadia Healthcare's risk/reward is attractive, especially if management sells the U.K. asset in the next six months, Jefferies analyst Brian Tanquilut tells investors in a research note. A sale should re-rate Acadia shares higher as it will de-lever the balance sheet and open the door to a resumption of acquisition, while also re-focusing investors on the "faster-growing, more stable" U.S. operations, contends the analyst. Tanquilut, who does not see much downside risk to estimates in the near-term, keeps a Buy rating on Acadia with a $40 price target.